Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Several other equities research analysts have also commented on RARE. Robert W. Baird restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 19th. Morgan Stanley restated an “equal weight” rating and issued a $71.00 price objective (up from $69.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, October 6th. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. JPMorgan Chase & Co. restated a “buy” rating and issued a $76.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Sunday, November 5th. Finally, Cowen restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 15th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $72.40.

Ultragenyx Pharmaceutical (NASDAQ RARE) traded down $1.99 during trading hours on Tuesday, hitting $45.81. The stock had a trading volume of 362,045 shares, compared to its average volume of 404,910. The stock has a market cap of $2,035.76, a price-to-earnings ratio of -6.57 and a beta of 1.83. Ultragenyx Pharmaceutical has a 52-week low of $43.14 and a 52-week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting the consensus estimate of ($1.87). The company had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.02 million. The company’s revenue for the quarter was up 81.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.64) earnings per share. equities research analysts expect that Ultragenyx Pharmaceutical will post -7.31 EPS for the current year.

A number of hedge funds have recently modified their holdings of RARE. Ameritas Investment Partners Inc. grew its position in shares of Ultragenyx Pharmaceutical by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 248 shares in the last quarter. Amalgamated Bank grew its position in shares of Ultragenyx Pharmaceutical by 7.6% during the second quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock valued at $309,000 after purchasing an additional 352 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Ultragenyx Pharmaceutical by 1.0% during the second quarter. Principal Financial Group Inc. now owns 73,412 shares of the biopharmaceutical company’s stock valued at $4,559,000 after purchasing an additional 722 shares in the last quarter. California Public Employees Retirement System grew its position in shares of Ultragenyx Pharmaceutical by 2.1% during the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biopharmaceutical company’s stock valued at $2,429,000 after purchasing an additional 800 shares in the last quarter. Finally, Swiss National Bank grew its position in shares of Ultragenyx Pharmaceutical by 1.8% during the third quarter. Swiss National Bank now owns 67,252 shares of the biopharmaceutical company’s stock valued at $3,582,000 after purchasing an additional 1,200 shares in the last quarter. Institutional investors and hedge funds own 94.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Ultragenyx Pharmaceutical (RARE) Downgraded to “Sell” at BidaskClub” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://theolympiareport.com/2018/01/17/ultragenyx-pharmaceutical-rare-downgraded-to-sell-at-bidaskclub-2.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.